Reuters logo
BRIEF-Innate Pharma announced data for two Phase I studies for lirilumab and nivolumab
2016年10月10日 / 早上6点21分 / 1 年前

BRIEF-Innate Pharma announced data for two Phase I studies for lirilumab and nivolumab

Oct 10(Reuters) - Innate Pharma SA :

* Announced on Sunday safety data for two Phase I studies conducted by Bristol-Myers Squibb

* Combination of lirilumab and nivolumab in Phase I study of advanced solid tumors showed no added toxicity over nivolumab monotherapy

* Data supports ongoing Phase I cohort expansion of lirilumab in combination with nivolumab

* Efficacy data will be presented at Society for Immunotherapy of Cancer 2016 conference

Source text for Eikon:

Further company coverage:

Gdynia Newsroom

我们的标准:汤森路透“信任原则”
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below